108 related articles for article (PubMed ID: 7708265)
1. Increase of sTNF receptor levels in acute renal allograft rejection after treatment with OKT3.
Bemelman FJ; Jansen J; van der Poll T; van Deventer SJ; ten Berge RJ
Nephrol Dial Transplant; 1994; 9(12):1786-90. PubMed ID: 7708265
[TBL] [Abstract][Full Text] [Related]
2. OKT3 escalating dose regimens provide effective therapy for renal allograft rejection.
Woodle ES; Bruce DS; Josephson M; Cronin D; Newell KA; Millis JM; Piper JB; O'Laughlin R; Thistlethwaite JR
Clin Transplant; 1996 Aug; 10(4):389-95. PubMed ID: 8884115
[TBL] [Abstract][Full Text] [Related]
3. Biological effects and fate of a soluble, dimeric, 80-kDa tumor necrosis factor receptor in renal transplant recipients who receive OKT3 therapy.
Wee S; Pascual M; Eason JD; Schoenfeld DA; Phelan J; Boskovic S; Blosch C; Mohler K; Cosimi AB
Transplantation; 1997 Feb; 63(4):570-7. PubMed ID: 9047153
[TBL] [Abstract][Full Text] [Related]
4. Natural serum TNF antagonists in end-stage renal failure and following renal transplantation.
Lambert C; Berthoux P; Vindimian M; Hacini J; Berthoux F
Nephrol Dial Transplant; 1994; 9(12):1791-6. PubMed ID: 7708266
[TBL] [Abstract][Full Text] [Related]
5. LPS-induced sTNF-receptor release in vivo in a murine model. Investigation of the role of tumor necrosis factor, IL-1, leukemia inhibiting factor, and IFN-gamma.
Bemelmans MH; Gouma DJ; Buurman WA
J Immunol; 1993 Nov; 151(10):5554-62. PubMed ID: 8228246
[TBL] [Abstract][Full Text] [Related]
6. The tumour necrosis factor family of receptors/ligands in the serum of patients with rheumatoid arthritis.
Robak T; Gladalska A; Stepień H
Eur Cytokine Netw; 1998 Jun; 9(2):145-54. PubMed ID: 9681390
[TBL] [Abstract][Full Text] [Related]
7. Soluble tumor necrosis factor (sTNF) receptors: a possible prognostic marker for bone marrow transplantation-related complications.
Or R; Kalinkovich A; Nagler A; Weisman Z; Naparstek E; Weiss L; Hahn T
Cytokines Mol Ther; 1996 Dec; 2(4):243-50. PubMed ID: 9384711
[TBL] [Abstract][Full Text] [Related]
8. Sparing of first dose effect of monovalent anti-CD3 antibody used in allograft rejection is associated with diminished release of pro-inflammatory cytokines.
Abbs IC; Clark M; Waldmann H; Chatenoud L; Koffman CG; Sacks SH
Ther Immunol; 1994 Dec; 1(6):325-31. PubMed ID: 7584508
[TBL] [Abstract][Full Text] [Related]
9. Effect of oral pentoxyfylline on the OKT3-induced cytokine-release syndrome among renal allograft recipients.
Vasquez EM; Pollak R
Clin Transplant; 1996 Jun; 10(3):294-7. PubMed ID: 8826669
[TBL] [Abstract][Full Text] [Related]
10. [OKT3 treatment of refractory renal allograft rejection].
Xu J; Ma J; Bai X
Zhonghua Wai Ke Za Zhi; 1997 Apr; 35(4):223-5. PubMed ID: 10374543
[TBL] [Abstract][Full Text] [Related]
11. Comparison of T10Bg.1A-31 and OKT3 in treating acute renal allograft rejection.
Lucas BA; Waid TH; Thompson JS; Brown SA; Munch LC; McKeown JW; Kryscio RJ; Prebeck RJ
Transplant Proc; 1993 Feb; 25(1 Pt 1):543-5. PubMed ID: 8438406
[No Abstract] [Full Text] [Related]
12. Serum levels of soluble tumor necrosis factor receptors and effects of interferon therapy in patients with chronic hepatitis C virus infection.
Itoh Y; Okanoue T; Ohnishi N; Sakamoto M; Nishioji K; Nakagawa Y; Minami M; Murakami Y; Kashima K
Am J Gastroenterol; 1999 May; 94(5):1332-40. PubMed ID: 10235215
[TBL] [Abstract][Full Text] [Related]
13. Increased levels of sTNF receptors following OKT3 treatment.
Bemelman FJ; Jansen J; van der Poll T; Hack CE; van Deventer SJ; ten Berge RJ
Transplant Proc; 1994 Dec; 26(6):3094-5. PubMed ID: 7998082
[No Abstract] [Full Text] [Related]
14. Renal transplant artery thrombosis following treatment of allograft rejection with monoclonal anti-CD3 antibodies (OKT3).
Noël C; Hazzan M; Coppin MC; Pruvot FR; Bridoux F; Lelièvre G
Transplant Proc; 1995 Aug; 27(4):2438-9. PubMed ID: 7652870
[No Abstract] [Full Text] [Related]
15. [Orthoclone OKT3 in the treatment of intractable acute renal allograft rejection].
Yu LX
Zhonghua Wai Ke Za Zhi; 1993 Dec; 31(12):754-5. PubMed ID: 8033708
[TBL] [Abstract][Full Text] [Related]
16. Polymorphism in the tumour necrosis factor receptor II gene is associated with circulating levels of soluble tumour necrosis factor receptors in rheumatoid arthritis.
Glossop JR; Dawes PT; Nixon NB; Mattey DL
Arthritis Res Ther; 2005; 7(6):R1227-34. PubMed ID: 16277675
[TBL] [Abstract][Full Text] [Related]
17. Use of OKT3 is associated with early and severe recurrence of hepatitis C after liver transplantation.
Rosen HR; Shackleton CR; Higa L; Gralnek IM; Farmer DA; McDiarmid SV; Holt C; Lewin KJ; Busuttil RW; Martin P
Am J Gastroenterol; 1997 Sep; 92(9):1453-7. PubMed ID: 9317061
[TBL] [Abstract][Full Text] [Related]
18. Pretreatment cytokine profiles of peripheral blood mononuclear cells and serum from patients with rheumatoid arthritis in different american college of rheumatology response groups to methotrexate.
Seitz M; Zwicker M; Villiger PM
J Rheumatol; 2003 Jan; 30(1):28-35. PubMed ID: 12508386
[TBL] [Abstract][Full Text] [Related]
19. Impact of first acute rejection episode and severity of rejection on cadaveric renal allograft survival.
Hariharan S; Alexander JW; Schroeder TJ; First MR
Clin Transplant; 1996 Dec; 10(6 Pt 1):538-41. PubMed ID: 8996775
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of the effects of TNF in renal allograft recipients using recombinant human dimeric tumor necrosis factor receptors.
Eason JD; Wee S; Kawai T; Hong HZ; Powelson JA; Widmer MB; Cosimi AB
Transplantation; 1995 Jan; 59(2):300-5. PubMed ID: 7839455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
